勘误：“SHP2抑制引发抗肿瘤免疫并与PD-1阻断协同作用”[《中国药理学通报》9 (2019) 304 - 315]的作者更正。
Erratum: Author correction to "SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade" [Acta Pharm Sin B 9 (2019) 304-315].
作者信息
Zhao Mingxia, Guo Wenjie, Wu Yuanyuan, Yang Chenxi, Zhong Liang, Deng Guoliang, Zhu Yuyu, Liu Wen, Gu Yanhong, Lu Yin, Kong Lingdong, Meng Xiangbao, Xu Qiang, Sun Yang
机构信息
State Key Laboratory of Pharmaceutical Biotechnology, Department of Biotechnology and Pharmaceutical Sciences, School of Life Sciences, Nanjing University, Nanjing 210023, China.
Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
出版信息
Acta Pharm Sin B. 2025 May;15(5):2810-2812. doi: 10.1016/j.apsb.2024.12.023. Epub 2024 Dec 23.
Abstract
[This corrects the article DOI: 10.1016/j.apsb.2018.08.009.].
摘要
[本文更正了文章的数字对象标识符：10.1016/j.apsb.2018.08.009。]
相似文献
1
Erratum: Author correction to "SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade" [Acta Pharm Sin B 9 (2019) 304-315].勘误：“SHP2抑制引发抗肿瘤免疫并与PD-1阻断协同作用”[《中国药理学通报》9 (2019) 304 - 315]的作者更正。
Acta Pharm Sin B. 2025 May;15(5):2810-2812. doi: 10.1016/j.apsb.2024.12.023. Epub 2024 Dec 23.
2
Erratum: Author correction to "Generation of Gal-enhanced bifunctional tumor vaccine" [Acta Pharm Sin B 12 (2022) 3177-3186].勘误：“Gal增强型双功能肿瘤疫苗的生成”[《中国药理学通报》12 (2022) 3177 - 3186]的作者更正。
Acta Pharm Sin B. 2025 Feb;15(2):1207. doi: 10.1016/j.apsb.2024.11.021. Epub 2024 Nov 29.
3
Erratum: Author correction to "The novel ER stress inducer Sec C triggers apoptosis by sulfating ER cysteine residues and degrading YAP ER stress in pancreatic cancer cells" [Acta Pharm Sin B 12 (2022) 210-227].勘误：作者对《新型内质网应激诱导剂Sec C通过硫酸化内质网半胱氨酸残基和降解YAP诱导胰腺癌细胞内质网应激从而引发凋亡》[《中国药理学报B》12 (2022) 210 - 227]一文的修正。
Acta Pharm Sin B. 2025 Feb;15(2):1208-1209. doi: 10.1016/j.apsb.2024.10.013. Epub 2024 Oct 30.
4
Erratum: Author correction to 'VEGFR2-targeted antibody fused with IFNamut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity' [Acta Pharm Sin B 11 (2021) 420-433].勘误：《靶向VEGFR2的抗体与IFNamut融合调节结直肠癌肿瘤微环境并表现出强大的抗肿瘤和抗转移活性》[《药学学报B》11 (2021) 420 - 433]的作者更正。
Acta Pharm Sin B. 2024 Jun;14(6):2790. doi: 10.1016/j.apsb.2024.02.014. Epub 2024 Feb 22.
5
Erratum: Author correction to 'Pharmacologically targeting molecular motor promotes mitochondrial fission for anti-cancer' [Acta Pharm Sin B 11 (2021) 1853-1866].勘误：“Pharmacologically targeting molecular motor promotes mitochondrial fission for anti-cancer” [《中国药理学报B》11 (2021) 1853-1866]的作者更正。
Acta Pharm Sin B. 2024 May;14(5):2358. doi: 10.1016/j.apsb.2024.02.013. Epub 2024 Feb 21.
6
Erratum: Author correction to "Tumor-microenvironment activated duplex genome-editing nanoprodrug for sensitized near-infrared titania phototherapy" [Acta Pharm Sin B (2022) 4224-4234].勘误：《肿瘤微环境激活的双链基因组编辑纳米前药用于敏化近红外二氧化钛光疗》[《药学学报B》（2022年）4224 - 4234]的作者更正。
Acta Pharm Sin B. 2024 Feb;14(2):897-899. doi: 10.1016/j.apsb.2023.09.002. Epub 2023 Sep 7.
7
Erratum: Author correction to "The neuroprotective effect of traditional Chinese medicinal plants-A critical review" [Acta Pharm Sin B 13 (2023) 3208-3237].勘误：《中药的神经保护作用——综述》[《药学学报B》13 (2023) 3208 - 3237]的作者更正。
Acta Pharm Sin B. 2025 Apr;15(4):2300. doi: 10.1016/j.apsb.2024.12.002. Epub 2024 Dec 3.
8
Erratum: Author correction to 'Co-delivery of nigericin and decitabine using hexahistidine-metal nanocarriers for pyroptosis-induced immunotherapeutics' [Acta Pharm Sin B 12 (2022) 4458-4471].勘误：“使用六组氨酸金属纳米载体共递送尼日利亚菌素和地西他滨用于焦亡诱导的免疫治疗”[《中国药理学报B》12 (2022) 4458 - 4471]的作者更正。
Acta Pharm Sin B. 2024 May;14(5):2359-2360. doi: 10.1016/j.apsb.2024.02.021. Epub 2024 Feb 29.
9
Erratum: Author correction to "Gas-propelled nanomotors alleviate colitis through the regulation of intestinal immunoenvironment-hematopexis-microbiota circuits" [Acta Pharm Sin B 14 (2024) 2732-2747].勘误：《气体驱动纳米马达通过调节肠道免疫环境-血液结合素-微生物群回路缓解结肠炎》[《药学学报B》14 (2024) 2732-2747]的作者更正。
Acta Pharm Sin B. 2024 Sep;14(9):4193. doi: 10.1016/j.apsb.2024.06.005. Epub 2024 Jun 15.
10
Erratum: Author correction to "Identification of anthelmintic parbendazole as a therapeutic molecule for HNSCC through connectivity map-based drug repositioning" [Acta Pharm Sin B 12 (2022) 2429-2442].勘误：作者对“通过基于连接图谱的药物重新定位鉴定抗蠕虫药帕苯达唑作为头颈部鳞状细胞癌的治疗分子”[《中国药理学通报》12 (2022) 2429-2442]进行的更正。
Acta Pharm Sin B. 2024 Nov;14(11):5089-5090. doi: 10.1016/j.apsb.2024.09.006. Epub 2024 Sep 10.
引用本文的文献
1
Role of the microbiome in diabetic wound healing: implications for new therapeutic approaches.微生物群在糖尿病伤口愈合中的作用：对新治疗方法的启示。
Arch Microbiol. 2025 Jul 31;207(9):208. doi: 10.1007/s00203-025-04399-9.
2
Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges.用于癌症治疗的下一代治疗性抗体：进展、应用与挑战
Mol Biotechnol. 2024 Sep 2. doi: 10.1007/s12033-024-01270-y.
Zotero 插件